此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia

2026年11月9日 更新者:Case Comprehensive Cancer Center

A Phase 2 Multi-Institutional Study of Combination of Luspatercept With Pacritinib (LusPACercept) in Patients With Myelofibrosis Associated Anemia and Thrombocytopenia

This study is for participants who have been diagnosed with myelofibrosis with cytopenia. Luspatercept and Pacritinib are experimental drug combination that works by blocking certain enzymes to calm an overactive inmmune system to reduce inflammation which would allow red blood cells to mature. The purpose of this study is to find out if the combination of Luspatercept and Pacritinib can help improve hemobglobin or transfusion dependents in participants with myelofibrosis with cytopenias.

研究概览

地位

尚未招聘

条件

干预/治疗

详细说明

Myelofibrosis is a type of bone cancer that mainly affects the elderly. Myeolofibrosis can either develop on its own, or it can be caused by other blood cell conditions. Myeolofibrosis causes scarring in the bone marrow that makes it hard to produce healthy read blood cells. This increases the risk of participants developing anemia at diagnosis, but eventually most affected participants develop anemia. Anemia is a complication of using Janus Kinase inhibitors, which are the main agents used to treat MF. Almost half of the participants who develop anemia require red blood cell transfusion support. Anemia causes poor quality of life, especially in participants who are transfusion dependent.

The goal of this study is to find out if using a combination of Luspatercept and Pacritinib can help decrease anemia in particpants with MF and improve the quality of life by requiring less blood transfusions. This combination works by blocking certain enzymes to calm an overactive immune system and reduce inflammation. This allows red blood cells to mature. Luspatercept will be given through subcutaneous injections on the first day of the study cycle, and pacritinib will be given in an oral pill that will be taken 2 times per day. About 50 participants are planned to be enrolled in the study.

研究类型

介入性

注册 (估计的)

50

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Akriti Jain, MD, FACP
  • 电话号码:216 445-7942
  • 邮箱:JAINA9@ccf.org

学习地点

    • Ohio
      • Cleveland、Ohio、美国、44196
        • Cleveland Clinic Foundation
        • 接触:
          • Akriti G Jain, MD, FACP
          • 电话号码:216 445-7942
          • 邮箱:JAINA9@ccf.org
        • 首席研究员:
          • Akriti G Jain, MD, FACP

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients with myelofibrosis as defined by WHO criteria - either primary or secondary myelofibrosis with:

    • Anemia:

      • Transfusion Dependent: ≥3 units transfused in the 12 weeks immediately preceding C1D1.
      • Non-Transfusion Dependent: had ≥3 Hb level measurements of ≤10 g/dL recorded on ≥3 different days with no RBC transfusions in the 12 weeks immediately preceding C1D1.
    • Thrombocytopenia: Platelet count of ≤150 at any time after signing informed consent.

  • Age ≥18 years

  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2.

  • A female of childbearing potential (FCBP) for this study is defined as a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (eg, has had menses at any time in the preceding 24 consecutive months). Females of childbearing potential (FCBP) participating in the study must:

    • Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the study, and after end of IP. This applies even if the participant practices true abstinence* from heterosexual contact.

    • Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception# 28 days prior to starting IP, during the study therapy (including dose interruptions), and for 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) after discontinuation of study therapy.

      • Subjects must avoid concomitant use of pacritinib with hormonal contraceptives except for intrauterine systems containing levonorgestrel. The effectiveness of hormonal contraceptives, except for intrauterine systems containing levonorgestrel, may be reduced when used with pacritinib. If contraception is needed or desired, an alternate contraceptive that is not affected by CYP3A4 inducers (e.g., an intrauterine system) or additional nonhormonal contraceptive (e.g., condoms) should be used when treated concomitantly with pacritinib, and for 30 days after last dose of pacritinib
  • Male participants must:

Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential who is or is not using contraception** while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) following IP discontinuation, even if he has undergone a successful vasectomy.

  • True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the participant. [Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.]

    • Agreement to use highly effective methods of contraception that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include: Placement of an intrauterine device (IUD); Bilateral tubal occlusion; Vasectomized partner; Sexual Abstinence.

      • Participant is willing and able to adhere to the study visit schedule and other protocol requirements including the use of the electronic patient reported outcomes device.
      • Participants must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Prior use of Luspatercept, Sotatercept, Elritercept or any other activin ligand traps, pacritinib or Momelotinib for any duration. Prior Ruxolitinib or Fedratinib are permissible with a wash out period of 2 weeks prior to C1D1.
  • Participant participation in any other clinical protocol or investigational trial that involves use of experimental therapy (including investigational agents) and/or therapeutic devices within 30 days or for investigational agents within five half-lives, whichever comes later, by the end of the screening period.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to luspatercept or pacritinib.
  • Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, gastrointestinal (GI) disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

4.2.5. Participant with anemia from cause other than MF or JAK2 inhibitor therapy (eg, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infection, or any type of known clinically significant bleeding or sequestration).

  • Participant use of hydroxyurea, immunomodulatory compounds such as pomalidomide, thalidomide, ESAs, androgenic steroids, strong CYP3A4 inhibitors and inducers, or other drugs with potential effects on hematopoiesis ≤ 2 weeks up to the end of the screening period.

    • Systemic corticosteroids are permitted for nonhematological conditions providing the participant is receiving a constant dose equivalent to ≤ 10 mg prednisone for the 4 weeks immediately up to the end of the screening period. Use of topical steroids (drops, inhaler, ointment etc.) are permitted.
    • Iron chelation therapy (ICT) is permitted providing the participant is receiving a stable dose for the 8 weeks up to the end of the screening period.
  • Participant with any of the following laboratory abnormalities at screening:

    • Neutrophils: < 0.5 x 109/L
    • White blood count (WBC): > 100 x 109/L
    • Peripheral blood myeloblasts: > 10%
    • PT or INR and PTT or aPTT >=1.5x ULN (this exclusion criteria would not apply for patients on anticoagulation).
    • Estimated glomerular filtration rate: < 30 mL/min/1.73 m2 (via the 4-variable modification of diet in renal disease [MDRD] formula) or nephrotic participants (eg, urine albumin-to-creatinine ratio > 3500 mg/g)
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT): > 3.0 x upper limit of normal (ULN)
    • Direct bilirubin: ≥ 2 x ULN
    • Severe hepatic impairment defined as Child-Pugh Class C (score ≥10)
    • Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (eg, ineffective erythropoiesis) or due to pre-existing Gilbert's disease.
  • Participant with prior history of malignancies, other than disease under study, unless the participant has been free of the disease for ≥ 3 years. However, participants with the following history/concurrent conditions are allowed (if they have already undergone treatment with curative intent):

    • Basal or squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system)
  • Participant with a major bleeding event (defined as symptomatic bleeding in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥ 2 g/dL or leading to transfusion of ≥ 2 units of packed red cells) in the last 3 months prior to the end of the screening period.

  • Participant with uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).

  • Pregnant or breastfeeding females.

  • Subjects with QTc >480 (unless QRS prolongation >120 msec, in which case QTC up to 500 is acceptable)

  • Subjects who have experienced a thrombotic or embolic event during 6 months prior to first planned dose of luspatercept.

  • Subjects who have experienced a major cardiac event within 6 months prior to enrollment, including but not limited to hospitalization for congestive heart failure (CHF), myocardial infarction (MI), or clinically significant arrhythmia requiring medical intervention

  • Subjects who have experienced symptomatic heart failure defined as New York Heart Association (NYHA) Class II or greater at the time of enrollment

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:LusPACercept combination

Luspatercept will be given through subcutaneous injection on Day 1of each cycle at a starting dose of 1.33 milligrams/kilogram and can go up to a maximum dose of 1.75 milligrams/kilogram. Pacritinib will be given twice daily orally at a dose of 200 milligrams. Each cycle lasts 21 days.

Luspatercept will be given through subjecutaneous injection on Day 1of each cycle at a dose of 1.33-1.75mg/kg.

Pacritinib will be given twice daily orally at a dose of 200mg.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Rate of major response for anemia
大体时间:week 24

The rate of major response for anemia is defined as per 2024 IWG-ELN response criteria for transfusion dependent and non-transfusion dependent partipants with myelofibrosis.

week 24

次要结果测量

结果测量
措施说明
大体时间
Rate of minor response for anemia
大体时间:week 24

Minor response for anemia is defined as per 2024 IWG-ELN response criteria for transfusion dependent and non-transfusion dependent partipants with myelofibrosis.

week 24
Safety of luspatrecept and pacritinib combination
大体时间:up to 24 weeks

Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) according to the CTCAE.

up to 24 weeks
Tolerability of luspatrecept and pacritinib combination
大体时间:up to 24 weeks

Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) according to the CTCAE.

up to 24 weeks
Proportion of participants achieving an anemia response
大体时间:up to 24 weeks

Anemia response during the entire treatment period, defined as a greater than or equal to 1.5 g/dL increase in hemoglobin during the entire treatment period

up to 24 weeks
Time to anemia response
大体时间:up to 24 weeks

Defined as time from first dose to first onset of anemia response during the 24 week primary treatment period

up to 24 weeks
Duration of anemia response
大体时间:up to 24 weeks

Defined as the amount of time from the onset of longest anemia response to loss of that response per IWG ELN 2024 criteria during the primary treatment period

up to 24 weeks
Proportion of participants achieving a greater than 50% reduction in total symptom score
大体时间:up to 24 weeks

As defined by the myeolofibrosis Symptom Assessment form v.4.0 (MF-SAF)

up to 24 weeks
Change in spleen size
大体时间:up to 24 weeks

Evaluate change in spleen size, assessed by spleen length on ultrasound and palpable spleen length below the left costal margin

up to 24 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Akriti Jain, MD, FACP、The Cleveland Clinic

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2029年1月1日

研究完成 (估计的)

2029年1月1日

研究注册日期

首次提交

2026年11月9日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月13日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • CASE2926

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All participant data will be shared via peer-reviewed publication as a combined summary. Any individual outcomes published per subject will be deidentified utilizing the subject ID (eg. Dose level, demographics, adverse events etc.)

IPD 共享时间框架

Data included in the peer reviewed publication will be publicly available. No raw data will be shared.

IPD 共享访问标准

A peer-reviewed publication will be made available according to the publishing journal's specifications. CCF personnel will not share study data apart from that which has been published publicly

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.